Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Broad and cross-neutralizing antibodies after primary vaccination with two different tick-borne encephalitis vaccines
2018-004674-94Phase 4Completed
- Sponsor
- Rīga Stradiņš University
- Start
- Mar 2019
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of FSME-IMMUN and Tick-borne encephalitis vaccine in tick-borne encephalitis (TBE) (2 arms), sponsored by Rīga Stradiņš University. Primary endpoint: Composite neutralizing antibody response. Started Mar 2019; status: completed.
02
Drugs
FSME-IMMUNTick-borne encephalitis vaccine
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2018-004674-94.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004674-94.